Indofarma (Persero) Tbk PT operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Indofarma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Novartis India Limited
sales of 8.08 billion Indian Rupees [US$125.45 million]
of which 81%
Daehwa Pharmaceutical Company Limited
of South Korea
(142.29 billion Korean Won [US$125.50 million]
Myungmoon Pharmaceutical Company Limited
based in South Korea
(142.18 billion Korean Won [US$125.40 million]
of which 97%
was Manufacture and Sale of Pharmaceuticals).
During the year ended December of 2016, sales at
Indofarma (Persero) Tbk PT were 1.67 trillion Indonesian Rupiahs (US$125.60 million).
increase of 3.3%
versus 2015, when the company's sales were 1.62 trillion Indonesian Rupiahs.
This was the fourth straight year of sales growth at Indofarma (Persero) Tbk PT.